GE HealthCare Technologies Inc. Common Stock Q3 2026 Earnings Recap

GE Healthcare’s shares rose 6.6% after earnings, as revenue and adjusted EPS growth, margin expansion, and a higher full-year outlook pointed to better-than-expected performance. Orders growth was more measured at 4%, against a strong prior-year comparison.

Key Takeaways

• Revenue was $5.5 billion, up 6.2% organically, with growth across all segments; reported product and service revenue grew 6.7% and 8.1%, respectively.
• Adjusted EBIT margin expanded 180 basis points to 16.6%; adjusted EPS rose 25.1% to $1.34.
• Organic orders grew 4%, versus 5.7% growth in the year-ago quarter; book-to-bill was 1.03x, and backlog reached $23.7 billion, up 12% year over year.
• Free cash flow was $793 million, up $310 million from the prior year.
• Management raised full-year 2026 guidance, citing business momentum; margin tailwinds included volume and price/cost actions, while memory-chip inflation and higher oil prices remained headwinds.